Skip to content

Company information lookup

INNATE IMMUNOTHERAPEUTICS LIMITED (IIL)

Development of a drug candidate to treat secondary progressive multiple sclerosis.

On this page you will find:

Delayed share price
Company announcements
Price history chart
Exchange Traded Options
ASX-Listed Emblem Company details
Closing prices
Dividends
Warrants & Structured Products

Delayed share price

Prices are delayed by 20 minutes unless stated otherwise in the Conditions. Retrieving any price indicates your acceptance of the Conditions.

Code Last % Chg Bid Offer Open High Low Vol
IIL 0.185 0% 0.185 0.190 0.000 0.000 0.000 0

INNATE IMMUNOTHERAPEUTICS LIMITED details

Please note: ASX relies on third parties to provide the information contained in the company details table, and therefore is unable to assume any responsibility for the accuracy or timeliness of the information.

Issuer Code IIL
Securities
Official Listing Date 23 December, 2013
GICS Industry Group Pharmaceuticals & Biotechnology
Exempt Foreign? No
Internet Address http://www.innateimmuno.com
Registered Office Address Suite 4.01, 35 Lime Street, SYDNEY, NSW, AUSTRALIA, 2000
Head Office Telephone (02) 8003 3650
Head Office Fax (02) 9225 5050
Share Registry COMPUTERSHARE INVESTOR SERVICES PTY LIMITED
YARRA FALLS, 452 JOHNSTON STREET, ABBOTSFORD, VIC, AUSTRALIA, 3067
Share Registry Telephone 1300 787 272
Directors / Senior Management
Mr Michael Quinn (Non Exec. Chairman)
Mr Simon Wilkinson (Managing Director)
Mr Christopher Collins (Non Exec. Director)
Ms Elizabeth Hopkins (Non Exec. Director)
Mr Andrew Sneddon (Non Exec. Director)
Mr Jeff Carter (CFO)
Company Secretary Mr Andrew John Cooke
Principal Activities Development of a drug candidate to treat secondary progressive multiple sclerosis.

INNATE IMMUNOTHERAPEUTICS LIMITED announcements

How are company announcements published on www.asx.com.au?

Date Price
sens.
Headline Pages PDF
31/10/2014 asterix Appendix 4C - September 2014 Quarter 5 PDF
24/10/2014   Appendix 3B - Employee Options 9 PDF
07/10/2014 asterix Update on Innate's Phase 2B trial and recent activities 3 PDF
18/09/2014   Change of Director's Interest Notice - S. Wilkinson 3 PDF
18/09/2014   Appendix 3B - AGM approved Options to CEO 9 PDF
21/08/2014   Results of Meeting - AGM 2 PDF
20/08/2014   CEO Address to AGM 11 PDF
20/08/2014   Chairman's Address to Shareholders - AGM 2 PDF
19/08/2014   Phase 2B WANRI Ethics Approval 2 PDF
29/07/2014 asterix Appendix 4C - June 2014 Quarterly Cash Flow Report 6 PDF

> search for past company announcements

Viewing Market Announcements:
Users of Adobe Acrobat Reader version 6.0.0 may have difficulty accessing PDF announcements. Symptoms include slow downloads, blank documents, and small white boxes appearing in the PDF. We recommend you download the latest version of the free Adobe Acrobat Reader. To check which version you have, open Adobe Acrobat Reader, click on 'Help', then click 'About Adobe Reader 6.0'.

Closing prices

Closing prices are displayed for the last 5 days on which the security traded on ASX within the last 6 months.

Date Last % Change High Low Vol *
30 Oct 2014 0.185 -2.63% 0.185 0.185 4,500
29 Oct 2014 0.190 5.56% 0.190 0.185 55,000
28 Oct 2014 0.180 0% 0.180 0.180 12,969
27 Oct 2014 0.180 0% 0.180 0.180 59,378
24 Oct 2014 0.180 5.88% 0.180 0.180 22,653

* Volume of shares shown represents only those shares traded on ASX.

INNATE IMMUNOTHERAPEUTICS LIMITED price history chart

* More charting options are available.

Dividends

How are dividends released on www.asx.com.au?

No dividends have been found for the security IIL. This is likely to be because a dividend has not been announced to the ASX by this company during the specified timeframe or a dividend has been announced but is not yet available on this website.

Exchange Traded Options

No Exchange Traded Options are available over the security IIL

Warrants & Structured Products

No warrants & Structured Products are available over the security IIL